Lv4
600 积分 2021-12-10 加入
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
7天前
已完结
Abiraterone Acetate–Associated Acute Pancreatitis: A Case Report
7天前
已完结
Cancer statistics, 2026: divergent trends and the implementation gap
13天前
已完结
Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy
1个月前
已完结
Field-effect-informed urine liquid biopsy for bladder cancer
2个月前
已完结
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial
3个月前
已完结
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
3个月前
已完结
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
4个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
4个月前
已完结
Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer, a multicentric analysis
4个月前
已完结
皖公网安备34019202002308
